Similarly, using a CXCR2 antagonist (aCXCR2) under the same experimental design (Fig. 5F, Fig. S6F), we observed a significant reduction in neutrophil infiltration (Fig. 5I, J, Fig. S6I-S6J), but the risk of RT-promoted DM was mitigated (Fig. 5H, Fig. S5H) without compromising local tumor control (Fig. 5G, Fig. S6G). Here, CXCR2 is linked to neoplasm.